A Randomized Clinical Study on Combination of Concurrent Chemo-Radiotherapy and Thalidomide for Middle-Late Esophageal Cancer

References

1. ↵
   1. Veuillez V,
   2. Rougier P,
   3. Seitz JF.

   The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer. Best Pract Res Clin Gastroenterol 2007; 21: 947-963.

   OpenUrlCrossRefPubMed
2. ↵
   1. Cooper JS,
   2. Guo MD,
   3. Herskovic A.

   Chemoradiotherapy of locally advanced esophageal cancer long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999; 281: 1623-1627.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Kimura H,
   2. Kato H,
   3. Tanaka N, et al.

   Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer. Anticancer Res 2008; 28: 165-169.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. Liu J,
   2. Lü CX,
   3. Wang JM.

   Concurrent chemoradiotherapy for patients with inoperable esophageal cancer. Zhonghua Fangshezhongliuxue Zazhi 2006; 15: 185-187 (Chinese).

   OpenUrl
5. ↵
   1. Yin WB.

   Radiotherapeutics on cancer. Beijing: Peking Union Medical College Press, 2008: 1349-1350.
6. ↵
   1. Zhou JC.

   Practical Medical Oncology. Beijing: People’s Medical Publishing House, 1999: 29-30.
7. ↵
   1. Neuner G,
   2. Patel A,
   3. Suntharalingam M, et al.

   Chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res 2009; 3: 57–65.

   OpenUrlPubMed
8. ↵
   1. Nishimaki T,
   2. Shimoji H,
   3. Sunagawa H.

   Recent changes and future roles of esophageal cancer surgery. Ann Thorac Cardiovasc Surg 2004; 10: 324-332.

   OpenUrlPubMed
9. ↵
   1. Cho SH,
   2. Shim HJ,
   3. Lee SR, et al.

   Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus 2008; 21: 697-703.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Feng W,
    2. Zhu SC.

    Research progress of relationship between vascular endothelial growth factor and esophageal cancer. Zhongguo Zhongliu 2006; 15: 600-603 (Chinese).

    OpenUrl
11. ↵
    1. Ogata Y,
    2. Fujita H,
    3. Yamana H, et al.

    Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: Long-term follow-up study. World J Surg 2003; 27: 584-589.

    OpenUrlCrossRefPubMed
12. ↵
    1. Syrigos KN,
    2. Zalonis A,
    3. Kotteas E, et al.

    Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev 2008; 27: 273–288.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Tang Y,
    2. Hu LN.

    Mechanism and applications of thalidomide in anticancer therapy. Guoji Zhongliuxue Zaqzhi 2007; 34: 414-417 (Chinese).

    OpenUrl
14. ↵
    1. Ansiaux R,
    2. Baudelet C,
    3. Jordan BF, et al.

    Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005; 11: 743-750.

    OpenUrlAbstract/FREE Full Text
15. ↵
    1. Kotoh T,
    2. Dhar DK,
    3. Masunaga R, et al.

    Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999; 125: 536-544.

    OpenUrlPubMedWeb of Science
16. ↵
    1. Merin JM,
    2. Lee FC.

    Palliative benefit for salvage treatment with capecitabine and thalidomide for gastric and/or esophageal adenocarcinoma: a retrospective case series. Proc Am Soc Clin Oncol 2002; 21: 2391.

    OpenUrl
17. ↵
    1. Chen EC,
    2. Liu MZ,
    3. Hu YH, et al.

    Multivariate analysis of prognosis of inoperable esophageal cancer patients undergoing concurrent radiochemotherapy. Aizheng 2005; 24: 731-734 (Chinese).

    OpenUrl
18. ↵
    1. Kato H,
    2. Fukuchi M,
    3. Manda R, et al.

    Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Anticancer Res 2003; 23: 3493-3498.

    OpenUrlPubMedWeb of Science
19. ↵
    1. Khan ZH,
    2. Simpson EJ,
    3. Cole AT, et al.

    Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003; 17: 677-682.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Gordon JN,
    2. Trebble TM,
    3. Ellis RD, et al.

    Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial. Gut 2005; 54: 540-545.

    OpenUrlAbstract/FREE Full Text
21. ↵
    1. Ghobrial IM,
    2. Rajkumar SV.

    Management of thalidomide toxicity. J Support Oncol 2003; 1: 194-205.

    OpenUrlPubMed
22. ↵
    1. Zangari M,
    2. Barlogie B,
    3. Anaissie E, et al.

    Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715-721.

    OpenUrlCrossRefPubMedWeb of Science